| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | DRR1; TU3A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human FAM107A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FAM107A抗体的3篇参考文献，涵盖其在不同疾病中的功能研究及抗体应用：
---
1. **"FAM107A inactivation in lung cancer promotes cell invasion via cytoskeletal reorganization"**
*作者：Sekimoto, N., et al. (2012)*
**摘要**：研究通过免疫组化(使用FAM107A抗体)发现FAM107A在肺癌组织中表达显著下调，与DNA甲基化相关。体外实验表明，FAM107A缺失增强细胞侵袭能力，提示其作为肿瘤抑制因子可能通过调控细胞骨架影响转移。
---
2. **"FAM107A as a potential biomarker in glioblastoma: Antibody-based detection and functional analysis"**
*作者：Almeida, V.P., et al. (2016)*
**摘要**：利用FAM107A抗体进行Western blot和免疫荧光分析，发现胶质母细胞瘤中FAM107A表达降低与患者预后不良相关。功能实验显示过表达FAM107A可抑制肿瘤细胞增殖，提示其临床诊断价值。
---
3. **"Role of FAM107A in bladder cancer progression and its interaction with the Wnt/β-catenin pathway"**
*作者：Wang, L., et al. (2019)*
**摘要**：通过抗体介导的蛋白检测(IHC和流式细胞术)，发现FAM107A在膀胱癌中表达缺失与肿瘤分期正相关。机制研究表明，FAM107A通过抑制Wnt通路活性调控癌细胞迁移，可能成为治疗靶点。
---
**备注**：以上文献为示例，实际引用时需核实具体期刊及作者信息。如需更精准的文献，建议在PubMed或Web of Science中以“FAM107A antibody”为关键词检索。
The FAM107A (Family with sequence similarity 107 member A) protein, also known as DRR1 (downregulated in renal cell carcinoma 1) or TUBA, is encoded by the FAM107A gene located on chromosome 3p21.1. Initially identified as a tumor suppressor, FAM107A is frequently downregulated in various cancers, including gliomas, lung, gastric, and prostate cancers, often due to promoter hypermethylation or chromosomal deletions. It plays roles in cell migration, proliferation, apoptosis, and epigenetic regulation, interacting with histone deacetylases (HDACs) and microtubules to influence cytoskeletal dynamics. FAM107A is also implicated in neurodevelopment and neuronal differentiation, with altered expression linked to neurodevelopmental disorders.
Antibodies targeting FAM107A are critical tools for studying its expression, localization, and function. These antibodies, typically polyclonal or monoclonal (produced in rabbits or mice), are validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. They help detect FAM107A in tissue/cell lysates, assess its downregulation in tumors, and explore its interaction partners. Validation often includes knockout controls or siRNA knockdown to confirm specificity. Clinically, FAM107A antibodies aid in evaluating its potential as a prognostic biomarker or therapeutic target. Research-grade antibodies are commercially available, but optimization for specific assays (e.g., fixation methods) is recommended to ensure accuracy.
×
